Cognitive processes of apathy in Huntington's disease show high sensitivity to disease progression.

Clinical Parkinsonism & Related Disorders(2022)

引用 0|浏览9
暂无评分
摘要
Background:Disease-modifying treatments for Huntington's disease (HD) are entering clinical trials: there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD. Objective:Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD. Methods:83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up. Results:The Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score). Conclusion:The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.
更多
查看译文
关键词
Biomarker,Clinical trials,Cognition,Huntington’s Disease,Neuropsychiatry
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要